RAS作为正性预测生物标志物:聚焦肺癌与结直肠癌患者
本文综述了RAS基因突变在非小细胞肺癌(NSCLC)和结直肠癌(CRC)中的预后与预测作用,汇总了靶向治疗在KRAS/NRAS突变患者中的临床结局证据,并概述了意大利不同实验室的真实世界RAS突变检测实践,据此提出知识库系统www.rasatlas.com以辅助精准肿瘤学管理。
要点
- KRAS在全部人类肿瘤中突变频率约22%,NRAS约8%,HRAS约3%。
- NSCLC与CRC中KRAS/NRAS突变的预后和预测价值受到重点关注。
- 提出知识库系统www.rasatlas.com辅助RAS突变患者的精准肿瘤学管理。
核心结论
- RAS基因突变在NSCLC和CRC中具有预后和预测作用,最新证据支持其作为正性预测生物标志物。
研究设计与样本
- 本文为综述,汇总了靶向治疗在NSCLC和CRC中KRAS及NRAS突变患者的临床结局证据,并概述意大利不同实验室的真实世界RAS突变检测实践。
主要发现
- 在全部人类肿瘤中,KRAS基因突变频率约22%,NRAS约8%,HRAS约3%。
- 大量文献数据研究了NSCLC和CRC中KRAS及NRAS突变患者接受靶向治疗的临床结局。
临床怎么用
- 提出知识库系统www.rasatlas.com,以支持医疗人员在精准肿瘤学背景下管理携带RAS基因突变的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rat sarcoma (RAS) oncogenes have intensively been investigated during the last decades. Taking into account all human tumours, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) gene is the most frequently mutated (about 22%) among the three isoforms, followed by Neuroblastoma RAS Viral Oncogene Homolog (NRAS) (8%) and Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) (3%). In the last years, careful attention has been paid on KRAS and NRAS gene mutations in non-small-cell lung cancer (NSCLC) and colorectal cancer (CRC) patients because of their prognostic and predictive roles. In particular, a large body of literature data has been generated investigating clinical outcomes of targeted treatments in NSCLC and CRC KRAS- and NRAS-mutated patients. The latest evidences are here reviewed, providing also an overview of the real-world RAS mutation testing practice across different Italian laboratories. On this basis, we propose a knowledge-based system, www.rasatlas.com, to support the healthcare personnel in the management of patients featuring RAS gene mutations in the landscape of precision oncology.
引用
- Malapelle U, Passiglia F, Cremolini C, et al. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. Eur J Cancer. 2021. PMID: 33588147. doi:10.1016/j.ejca.2021.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。